Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | May 12, 2026 | May 14, 2026 |
| REVVITY, INC.RVTY · Entity 3382 | Director | May 07, 2026 | May 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $533.92 · Expires 2036-05-11 | Direct | 525 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 525 · Balance 525 F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 234 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 234 · Balance 234 F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.
REVVITY, INC.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,368 |
Ending reported balance
After 2026-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-07 · Grant · Acquired 1,015 · Balance 6,103 F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Row 2 · 2026-05-07 · Grant · Acquired 1,265 · Balance 7,368 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 234 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000107 · wk-form4_1778792458.xml · derivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234 Underlying: Common Stock · 234 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 525 | $0.00 Strike: $533.92 | $0.00 |
DisclosureSEC source: 0000874716-26-000107 · wk-form4_1778792458.xml · derivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525 Underlying: Common Stock · 525 shares Expires 2036-05-11 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-216734 · ownership.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,368 Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-216734 · ownership.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,103 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 257 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-26-000088 · wk-form4_1778533863.xml · derivative · entry 3 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. F2 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:11 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000088 · wk-form4_1778533863.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 945 | Not disclosed Strike: $333.90 | Not disclosed |
DisclosureSEC source: 0000874716-26-000032 · wk-form4_1771542018.xml · derivative · entry 5 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 945 shares Expires 2032-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of stockholders, whichever event was earlier. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 519 | $628.56 | $326,222.64 |
DisclosureSEC source: 0000874716-26-000032 · wk-form4_1771542018.xml · nonDerivative · entry 3 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 945 | $628.65 | $594,070.47 |
DisclosureSEC source: 0000874716-26-000032 · wk-form4_1771542018.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,167 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 945 | $333.90 | $315,535.50 |
DisclosureSEC source: 0000874716-26-000032 · wk-form4_1771542018.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0000874716-25-000088 · wk-form4_1747170010.xml · derivative · entry 4 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,279 | $491.34 | $628,425.27 |
DisclosureSEC source: 0000874716-25-000088 · wk-form4_1747170010.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,167 Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,279 | $283.59 | $362,711.61 |
DisclosureSEC source: 0000874716-25-000088 · wk-form4_1747170010.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2025 Filed May 8, 2025 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000083 · wk-form4_1746745302.xml · derivative · entry 5 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Underlying: Common Stock · 257 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event earlier. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event earlier. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event earlier. Read SEC document |
| May 07, 2025 Filed May 8, 2025 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 600 | $0.00 Strike: $486.61 | $0.00 |
DisclosureSEC source: 0000874716-25-000083 · wk-form4_1746745302.xml · derivative · entry 4 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2035-05-06 F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2025 Filed May 8, 2025 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000083 · wk-form4_1746745302.xml · derivative · entry 3 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| May 06, 2025 Filed May 8, 2025 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000083 · wk-form4_1746745302.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,338 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-061822 · ownership.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,088 Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-061822 · ownership.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 28, 2026, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Read SEC document |
| November 27, 2024 Filed Nov 29, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 344 | $420.44 | $144,629.64 |
DisclosureSEC source: 0000874716-24-000144 · wk-form4_1732917601.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 905 Read SEC document |
| November 27, 2024 Filed Nov 29, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 224 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000144 · wk-form4_1732917601.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,249 Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000105 · wk-form4_1715209366.xml · derivative · entry 5 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event wa earlier. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event wa earlier. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event wa earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000105 · wk-form4_1715209366.xml · derivative · entry 4 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 609 | $0.00 Strike: $476.87 | $0.00 |
DisclosureSEC source: 0000874716-24-000105 · wk-form4_1715209366.xml · derivative · entry 3 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 609 shares Expires 2034-05-05 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000105 · wk-form4_1715209366.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,218 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052077 · ownership.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,676 Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 977 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052077 · ownership.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,458 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 22, 2025, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,404 | Not disclosed Strike: $245.79 | Not disclosed |
DisclosureSEC source: 0000874716-24-000064 · wk-form4_1709848802.xml · derivative · entry 4 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,404 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 6, 2020. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,404 | $562.98 | $790,427.01 |
DisclosureSEC source: 0000874716-24-000064 · wk-form4_1709848802.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,216 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $562.9801 to a high of $563.2160 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,404 | $245.79 | $345,089.16 |
DisclosureSEC source: 0000874716-24-000064 · wk-form4_1709848802.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016344 · ownership.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481 Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 217 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016344 · ownership.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 23, 2024, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 257 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-23-000083 · wf-form4_168453022946039.xml · derivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Underlying: Common Stock · 257 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 645 | $0.00 Strike: $487.12 | $0.00 |
DisclosureSEC source: 0000874716-23-000083 · wf-form4_168453022946039.xml · derivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645 Underlying: Common Stock · 645 shares Expires 2033-05-16 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:32 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-23-000057 · wf-form4_168418635262333.xml · derivative · entry 3 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. F2 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:32 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 344 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000057 · wf-form4_168418635262333.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,187 | Not disclosed Strike: $206.62 | Not disclosed |
DisclosureSEC source: 0000874716-23-000039 · wf-form4_168332406840001.xml · derivative · entry 4 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,187 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000039 · wf-form4_168332406840001.xml · nonDerivative · entry 3 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Sophie V. Vandebroek Revocable Trust Disclosed balance after: 8,173 Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,187 | $469.02 | $1,025,739.96 |
DisclosureSEC source: 0000874716-23-000039 · wf-form4_168332406840001.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 872 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $469.00 to a high of $469.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,187 | $206.62 | $451,877.94 |
DisclosureSEC source: 0000874716-23-000039 · wf-form4_168332406840001.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2022 Filed May 13, 2022 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-010580 · doc1.xml · derivative · entry 5 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344 Underlying: Common Stock · 224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. Read SEC document |
| May 11, 2022 Filed May 13, 2022 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-010580 · doc1.xml · derivative · entry 4 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568 Underlying: Common Stock · 344 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. F4 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 11, 2022 Filed May 13, 2022 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 945 | Not disclosed Strike: $333.90 | Not disclosed |
DisclosureSEC source: 0001567619-22-010580 · doc1.xml · derivative · entry 3 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945 Underlying: Common Stock · 945 shares Expires 2032-05-10 F4 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 11, 2022 Filed May 13, 2022 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 224 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-010580 · doc1.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 723 | Not disclosed Strike: $512.31 | Not disclosed |
DisclosureSEC source: 0001567619-21-010259 · doc1.xml · derivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Underlying: Common Stock · 723 shares Expires 2031-05-11 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-010259 · doc1.xml · derivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224 Underlying: Common Stock · 224 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date. F3 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,046 | Not disclosed Strike: $160.28 | Not disclosed |
DisclosureSEC source: 0001567619-21-004088 · doc1.xml · derivative · entry 4 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,046 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable on May 3, 2018. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,046 | $538.20 | $1,639,357.20 |
DisclosureSEC source: 0001567619-21-004088 · doc1.xml · nonDerivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,321 Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 3,046 | $160.28 | $488,212.88 |
DisclosureSEC source: 0001567619-21-004088 · doc1.xml · nonDerivative · entry 1 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009380 · doc1.xml · derivative · entry 2 Vandebroek Sophie V. · CIK 0001442078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.